These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2887660)

  • 1. Overview of pharmacotherapy: current status and future directions.
    Aman MG
    J Ment Defic Res; 1987 Jun; 31 ( Pt 2)():121-30. PubMed ID: 2887660
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychotropic drugs and mental retardation: 2. A comparison of psychoactive drug use before and after discharge from hospital to community.
    Thinn K; Clarke DJ; Corbett JA
    J Ment Defic Res; 1990 Oct; 34 ( Pt 5)():397-407. PubMed ID: 1979993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation.
    Schroeder SR; Rojahn J; Reese RM
    J Autism Dev Disord; 1997 Feb; 27(1):89-102. PubMed ID: 9018584
    [No Abstract]   [Full Text] [Related]  

  • 4. Polypharmacy in the treatment of subjects with intellectual disability.
    Häβler F; Thome J; Reis O
    J Neural Transm (Vienna); 2015 Aug; 122 Suppl 1():S93-100. PubMed ID: 24858727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
    Deb S; Unwin G; Deb T
    J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy for mental health problems in people with intellectual disability.
    Ji NY; Findling RL
    Curr Opin Psychiatry; 2016 Mar; 29(2):103-25. PubMed ID: 26779860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychopharmacoepidemiology of mental retardation: 1966 to 1995.
    Singh NN; Ellis CR; Wechsler H
    J Child Adolesc Psychopharmacol; 1997; 7(4):255-66. PubMed ID: 9542696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychotropic drug use with successful and unsuccessful community placed developmentally disabled groups.
    Harder SR; Kalachnik JE; Jensen MA; Feltz J
    Res Dev Disabil; 1987; 8(2):191-202. PubMed ID: 2890188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors.
    García-Domínguez L; Navas P; Verdugo MÁ; Arias VB; Gómez LE
    J Appl Res Intellect Disabil; 2022 Sep; 35(5):1109-1118. PubMed ID: 35384179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy in personality disorders.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2007 Jun; 45(6):15-9. PubMed ID: 17601155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and drug use in mentally retarded, emotionally disturbed adults.
    Matson JL; Kazdin AE; Senatore V
    Appl Res Ment Retard; 1984; 5(4):513-9. PubMed ID: 6151823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of and determinants for psychotropic drug use in an institution for the mentally retarded.
    Linaker OM
    Br J Psychiatry; 1990 Apr; 156():525-30. PubMed ID: 1974820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the residential (inpatient) treatment of individuals with a dual diagnosis.
    Spreat S; Behar D
    J Consult Clin Psychol; 1994 Feb; 62(1):43-8. PubMed ID: 7913478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiepileptic drugs with mood stabilizing properties and their relation with psychotropic drug use in institutionalized epilepsy patients with intellectual disability.
    Leunissen CL; de la Parra NM; Tan IY; Rentmeester TW; Vader CI; Veendrick-Meekes MJ; Aldenkamp AP
    Res Dev Disabil; 2011; 32(6):2660-8. PubMed ID: 21752594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study.
    Doan TN; Lennox NG; Taylor-Gomez M; Ware RS
    J Intellect Dev Disabil; 2013 Jun; 38(2):177-81. PubMed ID: 23550741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unnecessary psychotropic drug prescription in primary care for people with intellectual disability.
    Trollor J; Salomon C
    Evid Based Ment Health; 2016 May; 19(2):62. PubMed ID: 27075445
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicine use in people with intellectual disabilities: a Finnish nationwide register study.
    Nurminen F; Rättö H; Arvio M; Teittinen A; Vesala HT; Saastamoinen L
    J Intellect Disabil Res; 2023 Dec; 67(12):1291-1305. PubMed ID: 36372946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing psychotropic drug use in an institution for the retarded.
    LaMendola W; Zabaria ES; Carver M
    Hosp Community Psychiatry; 1980 Apr; 31(4):271-2. PubMed ID: 7390422
    [No Abstract]   [Full Text] [Related]  

  • 19. Principles of use of psychotropic drugs in children.
    Werry JS
    Drugs; 1979 Nov; 18(5):392-7. PubMed ID: 41701
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs.
    Scheifes A; Walraven S; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
    Res Dev Disabil; 2016; 49-50():13-21. PubMed ID: 26647003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.